{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=14",
    "query": {
      "intervention": "Protein Control",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 3497,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T00:55:03.728Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07128082",
      "title": "The Long COVID Treatment Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scripps Translational Science Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2025-10-30",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07128082"
    },
    {
      "nct_id": "NCT00845182",
      "title": "Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Healthy",
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone and Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2007-06",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2018-01-18",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845182"
    },
    {
      "nct_id": "NCT00591825",
      "title": "fMRI Study Examining Effects of D-cycloserine in Specific Phobia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Phobias"
      ],
      "interventions": [
        {
          "name": "D-cycloserine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2006-03",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2017-06-05",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00591825"
    },
    {
      "nct_id": "NCT02306876",
      "title": "A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06412562 3mg BID",
          "type": "DRUG"
        },
        {
          "name": "PF-06412562 15mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 77,
      "start_date": "2015-01-19",
      "completion_date": "2016-06-14",
      "has_results": false,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 3,
      "location_summary": "Arcadia, California • Glendale, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02306876"
    },
    {
      "nct_id": "NCT00141791",
      "title": "Study Evaluating Etanercept in Moderate to Severe Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2005-05",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2009-08-07",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Sarasota, Florida + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tallahassee",
          "state": "Florida"
        },
        {
          "city": "Valrico",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141791"
    },
    {
      "nct_id": "NCT01028976",
      "title": "Obesity, Inflammation and Oxidative Stress",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "C-reactive Protein",
        "Inflammation",
        "Obesity",
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "Vitamin C (ascorbic acid)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo tablet",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of California, Berkeley",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2010-01",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2015-12-02",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01028976"
    },
    {
      "nct_id": "NCT03911076",
      "title": "Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ASC-US",
        "ASC-H",
        "LSIL"
      ],
      "interventions": [
        {
          "name": "PVX-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "PapiVax Biotech, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 70 Years · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2019-05-22",
      "completion_date": "2022-06-08",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 6,
      "location_summary": "Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more",
      "locations": [
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Fairfield",
          "state": "Ohio"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Corpus Christi",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03911076"
    },
    {
      "nct_id": "NCT00022074",
      "title": "Gabapentin For the Control of Hot Flashes in Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anxiety Disorder",
        "Breast Cancer",
        "Depression",
        "Hot Flashes"
      ],
      "interventions": [
        {
          "name": "gabapentin",
          "type": "DRUG"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Gary Morrow",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "Up to 120 Years · Female only"
      },
      "enrollment_count": null,
      "start_date": "2001-07",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2015-10-15",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 18,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 15 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022074"
    },
    {
      "nct_id": "NCT03817125",
      "title": "Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Placebo for antibiotic",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin pretreatment",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for SER-401",
          "type": "DRUG"
        },
        {
          "name": "SER-401",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Parker Institute for Cancer Immunotherapy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-01-28",
      "completion_date": "2022-03-04",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03817125"
    },
    {
      "nct_id": "NCT00230776",
      "title": "A Controlled Pregabalin Trial In Fibromyalgia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "pregabalin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 740,
      "start_date": "2005-10",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2021-01-26",
      "last_synced_at": "2026-10-24T00:55:03.728Z",
      "location_count": 89,
      "location_summary": "Little Rock, Arkansas • Fresno, California • La Jolla, California + 76 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Pismo Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00230776"
    }
  ]
}